Religare Enterprises Shareholders Approve Office Shift and Director Appointment

Religare Enterprises Ltd's shareholders met via video conference on May 5, 2026, backing key corporate changes including the relocation of its registered office and the appointment of a new director. The meeting passed two significant resolutions.

Key Resolutions Passed at EGM

Shareholders approved moving the company's registered office from Delhi to Haryana. They also voted to appoint Arjun Lamba as a Whole Time Director, designated as Executive Director. The company is expected to file detailed voting results and the scrutinizer's report with stock exchanges and its website within two working days.

Strategic Importance of the Changes

These votes are significant steps in Religare's strategic transformation and efforts to strengthen governance. Moving the registered office aims to streamline operations, while appointing an Executive Director like Arjun Lamba is expected to boost management and execution.

Company Restructuring and Recent Appointments

Religare Enterprises has undergone significant restructuring and management changes. The Burman family gained a controlling stake in early 2025, prompting a board reconstitution to stabilize operations and enhance governance. The board had previously approved the office shift to Gurugram, Haryana, in February 2026, and Lamba's appointment as Executive Director in March 2026, pending shareholder approval. Lamba, with over 23 years in capital markets, has contributed to key acquisitions for the Burman Family.

Impact of the Decisions

The registered office will legally shift from Delhi to Haryana, changing its oversight jurisdiction. Arjun Lamba's appointment as a Director adds significant experience to the executive management team. The office move is also expected to offer potential administrative and operational efficiencies.

Past Regulatory Scrutiny and Challenges

Religare Enterprises has a history of regulatory scrutiny related to fund diversion. SEBI previously penalized entities for misusing funds from Religare Finvest, involving billions of rupees linked to former promoters. Former CEO Kavi Arora faced a two-year ban from securities markets. Religare Finvest also operated under the RBI's Corrective Action Plan (CAP) due to asset quality concerns, though these restrictions were lifted in July 2025.

Competitive Landscape

Religare operates in several competitive markets. Its subsidiary, Care Health Insurance, is a fast-growing standalone health insurer, reporting Gross Written Premium over ₹9,200 crore for FY2025. In retail broking, Religare Broking has over 1.2 million customers but contends with discount brokers such as Zerodha and Groww. For SME lending, Religare Finvest competes with firms like Bajaj Finance and Poonawalla Fincorp.

Key Performance Metrics

Care Health Insurance reported Gross Written Premium exceeding ₹9,200 crore for FY2025, capturing about 4.7% of the health insurance market. Religare Broking Limited serves over 1.2 million customers across more than 1,100 locations.

What Investors Are Watching

Investors will watch for the official announcement of the EGM's voting results and the scrutinizer's report. Confirmation of regulatory compliance for the office relocation and director appointment is also key. Practical implementation of the office move and observing Arjun Lamba's contribution to executive management and strategic initiatives will be closely monitored.